Happy to be here at #ASCO26 for an excellent NSCLC session hosted by Dr. @BrunaPellini !
Hoping to find HARMONi?🧘
Sing a LIBRETTO? 🎤
Earn your CROWN?
Become an ALCHEMIST?
Wield a TRITON?
Look forward to these trials and more!
🫁 Poor PS, high PD-L1—can IO still work?
IFCT-1802 SAVIMMUNE (Ph2) evaluated 1L durvalumab in stage IV #NSCLC with ECOG PS 2–3 & PD-L1 ≥25%.
◼️ Grade ≥3 TRAEs (8 wks): 10%
◼️ ORR: 26%
◼️ 1-yr OS: 40%
◼️ PS improvement at 8 wks: 44%
Important data for a population often excluded from trials. @LungCancerRx@OncoAlert@oncodaily@JTOonline https://t.co/slBfnKXnLc
Check our viewpoint published @JAMA_current#MedEd
Abstract Factory—Research Culture Harming Medical Education
The "abstract factory" is destroying medical education. Trainees and junior faculty compete with abstract counts instead of meaningful research. Result: inflated CVs, diluted conferences. We shouldn't celebrate this—you don't need publications to be a great doctor.
➡️https://t.co/IMBhy45L1K
@utswcancer@rajshekharucms@HiraSMian@ManniMD1@HemOncFellows@ASCOTECAG
In this @AATSJournals article with @MDAndersonNews@lungoncdoc, we discuss clinicians’ responsibility to educate: Clear and evidence based messaging shape patient understanding, and social media is an important venue for sharing accurate information. https://t.co/mCNveIeC8n
On the stage at our inaugural #PRIMONYLung25 discussing important 1L clinical updates for patients with mNSCLC without AGAs.
Key pts discussed:
-Can’t just lump all “high PDL1” dz
-STK11/KEAP1 matter
-Squamous histology impactful
-5yr OS rates informative
When lung cancer is diagnosed early, survival rates are much higher.
We must continue to advance therapies—but the greatest impact will likely come from earlier detection.
@LungAssociation
5 year outcomes with 1L cemiplimab vs chemo in PD-L1 high NSCLC from phase III EMPOWER-Lung 1 @JTOonline. OS favors cempilimab (26.1 vs 13.3m, HR 0.59, 5y OS rate 29% vs 15%) with better outcomes for PD-L1 ≥ 90%, where mOS 38.8m, 5y OS rate 39.8%.
https://t.co/ho0yWyWNEB
⏰ Timing might matter in NSCLC! A bi-continental study shows morning immuno-chemotherapy (before 11:30 AM) nearly doubled survival vs afternoon dosing (33.0 vs 19.5 months). RWE from France & China—time to rethink the schedule of immunotherapy! https://t.co/9JhZEnoyZz
Honored to join @FOX26Houston this morning to shed light on the rising rates of lung cancer in patients with no smoking history. The message remains the same: all you need to be at risk for lung cancer is to have lungs!
@MDAndersonNews#EndCancer